ArticleBeilstein journal of nanotechnology2021
Identifying diverse metal oxide nanomaterials with lethal effects on embryonic zebrafish using machine learning.
Article in Beilstein journal of nanotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Bridging Nano-Interface Interactions and Organ-Specific Toxicity: A Review of Machine Learning for Nanomaterials Risk Assessment.Molecules (Basel, Switzerland) · 2026Review
- New Frontiers in AI-Nano Converged Platforms for Intelligent Diagnostics, Therapeutics, and Safety Evaluation.Chem & bio engineering · 2026Review
- Introducing third-generation periodic table descriptors for nano-qRASTR modeling of zebrafish toxicity of metal oxide nanoparticles.Beilstein journal of nanotechnology · 2024Article
- Identifying diverse metal oxide nanomaterials with lethal effects on embryonic zebrafish using machine learning.Beilstein journal of nanotechnology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Manufacturers of nanomaterial-enabled products need models of endpoints that are relevant to human safety to support the "safe by design" paradigm and avoid late-stage attrition. Increasingly, embryonic zebrafish (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.